Eikon Therapeutics has announced that it has closed a $148 million Series A financing led by The Column Group with participation from Foresite Capital, Innovation Endeavors and Lux Capital. The company also announced the appointment of Roger M. Perlmutter, M.D., Ph.D., as its new CEO. Eikon’s drug discovery platform evolved from super-resolution microscopy, a ground-breaking…
PerkinElmer expands Signals Informatics capabilities in biologics drug discovery
PerkinElmer announced this week its documentation, workflow and decision-making Signals informatics platform is being expanded to build on existing capabilities in the biologics drug discovery space. This comes through a collaboration with life science software company, Insightful Science. With the collaboration, pharmaceutical and academic research teams can bring together the power of the PerkinElmer Signals…
2021 Global R&D Funding Forecast released
By Tim Studt, Contributing Editor For 62 years, R&D World and its predecessors have published an annual R&D funding forecast. These reports predict the combined dollar amount of R&D investments expected by industry, government and academia for the upcoming calendar year. Over those years, the publications these reports have appeared in have changed their ownership…